C. N, Sundar Rns, Kumar Hks, Nataraju G, Esaivani Kb
{"title":"Tumor budding in colorectal adenocarcinoma using cytokeratin 20 immunostaining","authors":"C. N, Sundar Rns, Kumar Hks, Nataraju G, Esaivani Kb","doi":"10.17727/jmsr.2023/11-53","DOIUrl":null,"url":null,"abstract":"Introduction: Colorectal cancer is the third most common cancer worldwide and second most common fatal cancer. Tumor budding is an emerging prognostic indicator in cancers. Though tumor budding can be assessed using Hematoxylin and Eosin stain, sometimes peritumoral inflammation and reactive stromal fibrosis obscures the tumor buds. The present study aimed to assess tumor budding using cytokeratin 20 immunohistochemistry in colorectal cancers. Methods: This is a cross sectional study which included 30 cases of colorectal carcinomas. cytokeratin 20 stained slides of colorectal carcinoma were assesed for tumor budding using International Tumor Budding Consensus Conference (ITBCC) 2016 consensus criteria and compared with AJCC cancer stage. Results: Demographic analysis showed peak incidence of colorectal cancer in the age group of 55-64 years (33.3%) and male: female ratio of 1.14:1. Majority of the tumors with score 1(23.3%) showed stage I. While tumors with score 2 had similar incidence of stage I (16.6%) and II (16.6%) and lesser incidence of stage III (3.33%). Most of the tumors with score 3 tumor budding had stage III tumors (26.67%). The p value is < 0.0001, which is statistically significant. Tumor budding signifies the biological and molecular phenomenon of epithelial-mesenchymal transition in the tumor microenvironment. Loss of E-cadherin, alterations in transcription factors including SNAIL, ZEB, TWIST etc and switching of CMS2 to CMS4 are some of the recorded molecular profiles responsible for tumor budding. Conclusion: This study concludes that the tumor stage increases with tumor budding and thus is a reliable marker in predicting the prognosis. This study also states that immunohistochemical study gives objective scoring of tumor buds in colorectal cancers. Keywords: tumor budding; colorectal cancer; cytokeratin 20; prognostic marker","PeriodicalId":32890,"journal":{"name":"Journal of Medical and Scientific Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical and Scientific Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17727/jmsr.2023/11-53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Colorectal cancer is the third most common cancer worldwide and second most common fatal cancer. Tumor budding is an emerging prognostic indicator in cancers. Though tumor budding can be assessed using Hematoxylin and Eosin stain, sometimes peritumoral inflammation and reactive stromal fibrosis obscures the tumor buds. The present study aimed to assess tumor budding using cytokeratin 20 immunohistochemistry in colorectal cancers. Methods: This is a cross sectional study which included 30 cases of colorectal carcinomas. cytokeratin 20 stained slides of colorectal carcinoma were assesed for tumor budding using International Tumor Budding Consensus Conference (ITBCC) 2016 consensus criteria and compared with AJCC cancer stage. Results: Demographic analysis showed peak incidence of colorectal cancer in the age group of 55-64 years (33.3%) and male: female ratio of 1.14:1. Majority of the tumors with score 1(23.3%) showed stage I. While tumors with score 2 had similar incidence of stage I (16.6%) and II (16.6%) and lesser incidence of stage III (3.33%). Most of the tumors with score 3 tumor budding had stage III tumors (26.67%). The p value is < 0.0001, which is statistically significant. Tumor budding signifies the biological and molecular phenomenon of epithelial-mesenchymal transition in the tumor microenvironment. Loss of E-cadherin, alterations in transcription factors including SNAIL, ZEB, TWIST etc and switching of CMS2 to CMS4 are some of the recorded molecular profiles responsible for tumor budding. Conclusion: This study concludes that the tumor stage increases with tumor budding and thus is a reliable marker in predicting the prognosis. This study also states that immunohistochemical study gives objective scoring of tumor buds in colorectal cancers. Keywords: tumor budding; colorectal cancer; cytokeratin 20; prognostic marker
导言结直肠癌是全球第三大常见癌症,也是第二大致命癌症。肿瘤萌芽是癌症预后的一个新指标。虽然可以用苏木精和伊红染色法评估肿瘤萌芽,但有时瘤周炎症和反应性基质纤维化会掩盖肿瘤萌芽。本研究旨在利用细胞角蛋白20免疫组化技术评估结直肠癌中的肿瘤萌芽。研究方法采用国际肿瘤萌芽共识会议(ITBCC)2016年共识标准对细胞角蛋白20染色的结直肠癌切片进行肿瘤萌芽评估,并与AJCC癌症分期进行比较。结果人口统计学分析显示,结直肠癌的发病高峰在55-64岁年龄组(33.3%),男女比例为1.14:1。大多数得分 1 的肿瘤(23.3%)为 I 期,得分 2 的肿瘤 I 期(16.6%)和 II 期(16.6%)发病率相似,III 期发病率较低(3.33%)。大部分得分 3 的肿瘤萌芽为 III 期肿瘤(26.67%)。P 值小于 0.0001,具有统计学意义。肿瘤出芽标志着肿瘤微环境中上皮-间质转化的生物学和分子现象。E-cadherin的缺失、转录因子(包括SNAIL、ZEB、TWIST等)的改变以及CMS2向CMS4的转换是导致肿瘤出芽的一些记录在案的分子特征。结论本研究得出结论,肿瘤分期随肿瘤出芽而增加,因此是预测预后的可靠标志物。本研究还指出,免疫组化研究可对结直肠癌中的肿瘤萌芽进行客观评分。关键词:肿瘤萌芽;结直肠癌;细胞角蛋白20;预后标志物